Aix-Marseille Université
AD2P (also locally referred to as the “Plateforme de Criblage Marseille-Luminy” (PCML)) plays a significant role in the research field of antivirals against emerging viruses.
Indeed, the facility has developed and offers expertise in the screening of viral enzyme inhibitors, protein/protein interactions, clinical virus isolates, the supply of chemical libraries, as well as in the development of new technologies and drug design.
LS1_11 - Chemical biology - Molecules of Life: Biological Mechanisms, Structures and Functions
LS7_9 - Public health and epidemiology - Prevention, Diagnosis and Treatment of Human Diseases
LS6_6 - Infectious diseases - Immunity, Infection and Immunotherapy
LS8_4 - Population biology, population dynamics, population genetics - Environmental Biology, Ecology and Evolution
LS9_2 - Applied genetics, gene editing and transgenic organisms - Biotechnology and Biosystems Engineering
HTS
Antivirals
Emerging Viruses
2P2I
AD2P is accessible to scientific communities of both the academic and private sectors, upon request.
Here below are examples of the services AD2P can provide:
- Screening of antivirals against emerging viruses (e.g., Dengue, Zika, WNV, Chik, VEEV, SARS, MERS, TBE, JEV).
- Screening against clinical virus isolates; development of new antiviral strategies (e.g., HTRF, 2P2I).
- Structure-based drug design; cheminformatics; and creation of chemolibraries.
- Hit-to-lead optimisation.